Recently, it was demonstrated that the human recombinant form of the proteoglycan 4 (PRG4) inhibits TGFβ-mediated invasiveness of breast cancer cells by binding to CD44 and affecting its downstream signaling pathway23. This evidence concerns the gene PRG4 and breast cancer.